PMID- 34205099
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210705
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 13
IP  - 11
DP  - 2021 Jun 3
TI  - Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable 
      Hepatocellular Carcinoma in Real-World Clinical Practice.
LID - 10.3390/cancers13112786 [doi]
LID - 2786
AB  - BACKGROUND: Atezolizumab plus bevacizumab was approved for patients with 
      hepatocellular carcinoma (HCC). Although clinical trials have revealed its 
      efficacy, the outcomes in the real-world clinical practice are unclear. We 
      retrospectively evaluated the efficacy and safety of atezolizumab plus 
      bevacizumab for HCC. MATERIALS AND METHODS: This is a multicenter study conducted 
      between November 2020 and March 2021. Among the 61 patients, 51 were assessed for 
      progression-free survival (PFS), therapeutic response, and adverse events (AEs). 
      RESULTS: The median PFS was 5.4 months. The objective response rate (ORR) was 
      35.3%. The disease control rate (DCR) was 86.3%. The incidence rates of AEs at 
      any grade and grade >3 were 98.0% and 29.4%, respectively. The most frequent AE 
      at any grade and grade >3 was hepatic disorder. In patients with a previous 
      history of molecular targeted agent (MTA) or the degree of albumin-bilirubin 
      (ALBI) grade, there were no significant differences in the PFS, ORR, DCR, and 
      incidence rates of AEs. CONCLUSION: The study demonstrated that atezolizumab plus 
      bevacizumab was effective and safe for patients with HCC even in the real-world 
      setting including patients with a previous MTA history or other than ALBI grade 
      1.
FAU - Iwamoto, Hideki
AU  - Iwamoto H
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
AD  - Department of Gastroenterology, Iwamoto Internal Medicine Clinic, Kitakyushu 
      802-0832, Japan.
FAU - Shimose, Shigeo
AU  - Shimose S
AUID- ORCID: 0000-0003-2068-8386
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - Noda, Yu
AU  - Noda Y
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - Shirono, Tomotake
AU  - Shirono T
AUID- ORCID: 0000-0002-2662-6779
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - Niizeki, Takashi
AU  - Niizeki T
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - Nakano, Masahito
AU  - Nakano M
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - Okamura, Shusuke
AU  - Okamura S
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - Kamachi, Naoki
AU  - Kamachi N
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - Suzuki, Hiroyuki
AU  - Suzuki H
AUID- ORCID: 0000-0003-2383-5038
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - Sakai, Miwa
AU  - Sakai M
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - Kajiwara, Akira
AU  - Kajiwara A
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - Itano, Satoshi
AU  - Itano S
AD  - Department of Gastroenterology, Kurume Central Hospital, Kurume 830-0001, Japan.
FAU - Tanaka, Masatoshi
AU  - Tanaka M
AUID- ORCID: 0000-0002-4791-8885
AD  - Department of Gastroenterology, Yokokura Hospital, Miyama 839-0295, Japan.
FAU - Yamaguchi, Taizo
AU  - Yamaguchi T
AD  - Department of Gastroenterology, Iwamoto Internal Medicine Clinic, Kitakyushu 
      802-0832, Japan.
FAU - Kuromatsu, Ryoko
AU  - Kuromatsu R
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - Koga, Hironori
AU  - Koga H
AUID- ORCID: 0000-0001-5814-9543
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - Torimura, Takuji
AU  - Torimura T
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, Kurume 830-0011, Japan.
FAU - On Behalf Of The Kurume Liver Cancer Study Group Of Japan
AU  - On Behalf Of The Kurume Liver Cancer Study Group Of Japan
LA  - eng
PT  - Journal Article
DEP - 20210603
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC8199943
OTO - NOTNLM
OT  - atezolizumab
OT  - bevacizumab
OT  - hepatocellular carcinoma
OT  - real-world data
COIS- The authors declare no conflict of interest.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/03 06:01
PMCR- 2021/06/03
CRDT- 2021/07/02 01:23
PHST- 2021/04/25 00:00 [received]
PHST- 2021/05/24 00:00 [revised]
PHST- 2021/06/02 00:00 [accepted]
PHST- 2021/07/02 01:23 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/03 06:01 [medline]
PHST- 2021/06/03 00:00 [pmc-release]
AID - cancers13112786 [pii]
AID - cancers-13-02786 [pii]
AID - 10.3390/cancers13112786 [doi]
PST - epublish
SO  - Cancers (Basel). 2021 Jun 3;13(11):2786. doi: 10.3390/cancers13112786.